Abstract Details

Title Rising Mortality Related to Early-Onset Alzheimer’s Disease in the United States: Trends and Disparities 2003-2023

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) S15 - Diagnostics, Mechanics, and Mortality of Alzheimer's Disease and Related Dementias (1:36 PM-1:48 PM)

Poster/Presentation
Number 004

Objective We aimed to examine nationwide demographic trends of early-onset Alzheimer’s disease-related mortality (EOAD-RM) from 2003 to 2023. Additionally, we analyzed differences in EOAD-RM based on sex, race/ethnicity, and region.

Background The overall prevalence of early-onset Alzheimer’s disease (EOAD), defined as onset prior to 65 years, is estimated to be around 5-10%. While EOAD is rare, it is characterized by a more aggressive course than late-onset AD. Epidemiological data on EOAD and its related mortality remain limited.

Design/Methods This retrospective population-based study utilized data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiological Research (CDC WONDER) mortality records. We used International Classification of Diseases (ICD) code G30.0 to identify EOAD-RM. Data were stratified by sex, race/ethnicity, and region. Trends in age-adjusted mortality rates (AAMRs) were examined using joinpoint regression.

Results There were 5,167 EOAD-related deaths (62.4% female) in the United States over the study period. From 2003 to 2023, the AAMR increased approximately 25-fold, from 0.08 to 2.06 (95% CI 1.93-2.20) per one million population. The annualized percentage change (APC) was 19.9% (95% CI 17.98-21.82) between 2015 and 2023. This increase in mortality was seen irrespective of sex, race/ethnicity, or region. During the same period, females exhibited a faster rise in AAMR compared to males. Black or African American individuals showed the greatest relative increase (206%) between 2018 and 2023. Regionally, the West and Midwest experienced the largest rises, with AAMRs increasing 632% and 741%, respectively.

Conclusions The rapid increase in EOAD-RM in recent years underscores the growing burden of EOAD in the United States, the need to investigate underlying causes, and the need for effective treatments. These findings may shed light on EOAD prevalence, incidence, and contributing factors in order to improve clinical outcomes.

Authors/Disclosures
Keara Kennedy PRESENTER	Miss Kennedy has nothing to disclose.
Andy Song, Medical Student	Mr. Song has nothing to disclose.
Maura Hackett, Medical student	Ms. Hackett has nothing to disclose.
Ali M. Al-Salahat, MBBS (Creighton University - Neurology Program)	Dr. Al-Salahat has nothing to disclose.
Himanshu Verma, MBBS (Creighton University School of Medicine)	Dr. Verma has nothing to disclose.
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine)	Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.

��ɫ��

��ɫ��